Randomized open-label study of patients with CKD on dialysis 3–12 months with iPTH 300–800 pg/mL who were randomized to receive Sensipar^® with or without vitamin D and phosphate binders or vitamin D and phosphate binders, if prescribed, per physician discretion (N = 309). The primary endpoint was proportion of patients achieving a ≥ 30% PTH reduction from baseline at 6 months. Total treatment duration was 12 months, followed by a 4-week washout phase in which vitamin D and Sensipar^® were withheld in both treatment arms.¹²

A database of claims and/or electronic medical records consisting of de-identified longitudinal prescription data from approximately 150 million patients. A 12-month observation period was used to assess patient persistence (prescription refills). Patients with a first-time prescription and no prior use of Sensipar^® within the previous 12 months were included;  (n = 123,931; excluded patients ages 0–19). A 90-day period between refills was allowed.¹⁸